|
|
|
|
|
|
|
Highlights from the 2024 American Society for Radiation Oncology Annual Meeting |
|
|
|
|
| A Digital Pathology MMAI Algorithm is Associated with Pro-Metastatic Genomic Pathways in Oligometastatic Prostate Cancer |
| Yang Song |
| Yang Song presented findings on the ArteraAI Prostate Test, a digital pathology multimodal artificial intelligence (MMAI) algorithm, which was shown to predict overall survival in patients with oligometastatic castration-sensitive prostate cancer. The study found that higher MMAI scores correlated with mutations in pro-metastatic genomic pathways, including increased frequencies of BRCA2/ATM and WNT pathway mutations, while lower scores were associated with better-prognosis SPOP mutations. |
|
|
|
|
|
| Validation of a Digital Pathology-Based MMAI Model in Oligometastatic Castration-Sensitive Prostate Cancer, including Patients from the STOMP and ORIOLE Phase II Randomized Trial |
| Philip Sutera, MD |
| Philip Sutera presented findings validating the ArteraAI MMAI model as a prognostic biomarker in oligometastatic castration-sensitive prostate cancer, utilizing data from the STOMP and ORIOLE Phase II trials. The study revealed that patients with high MMAI scores had significantly worse overall survival rates and were more likely to benefit from metastasis-directed therapy, suggesting that this digital pathology-based model can enhance personalized treatment approaches. |
|
|
|
|
|
|
|
|
|
|
| A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African American and Non-African American Men with Prostate Cancer (VANDAAM STUDY) |
| Kosj Yamoah, MD, PhD |
| Kosj Yamoah presented the VANDAAM Study, which examined the impact of the Decipher genomic risk classifier on treatment recommendations for African American and non-African American men with prostate cancer. The study found that the Decipher score is a strong predictor of biochemical recurrence within two years for both groups, with African American men showing improved recurrence-free survival with radiotherapy compared to those receiving radical prostatectomy. |
|
|
|
|
|
| Examination of Decipher Prostate Genomic Classifier in Patients with De Novo Metastatic Disease from a Large Scale Real-World Clinical and Transcriptomic Data Linkage |
| Shalini Moningi, MD |
| Shalini Moningi presents the findings on the Decipher prostate genomic classifier's role in patients with de novo metastatic prostate cancer, utilizing a large-scale linkage of clinical and transcriptomic data. The study revealed that these patients exhibited higher PSA levels and very high Decipher scores compared to localized cases, suggesting a more aggressive disease profile. |
|
|
|
|
|
| The Interplay between Acute and Late Toxicity among Patients Receiving Prostate Radiotherapy: A Pooled Analysis of 7 Randomized Trials |
| John Nikitas, MD |
| John Nikitas presents the findings on the relationship between acute and late toxicity in patients receiving prostate radiotherapy, based on pooled data from seven randomized trials. The analysis included 7,555 patients and revealed that acute grade 2+ genitourinary and gastrointestinal toxicities were significantly associated with late toxicities, both physician-reported and patient-reported. |
|
|
|
|
|
| Prostate CAncer integrated Risk Evaluation (P-CARE): A Model to Stratify Risk of Any, Metastatic, and Fatal Prostate Cancer
|
| Anna Dornisch, MD
|
| Anna Dornisch presents the Prostate Cancer integrated Risk Evaluation (P-CARE), a novel model designed to stratify risk for any, metastatic, and fatal prostate cancer. Given the controversial nature of prostate cancer screening, P-CARE integrates a polygenic hazard score based on 290 genomic variants, along with family history and genetic ancestry, to provide a more objective assessment of risk. The study used data from the Million Veteran Program, identifying 601 candidate variants for the updated polygenic score.
|
|
|
|
|
|
| Impact of Hyaluronic Acid Rectal Spacer Quality Score and Fischer-Valuck Spacer Symmetry Score on Rectal Dosimetry and Acute and Late Gastrointestinal Toxicity Outcomes – An Australian Experience |
| Yuan-Hong Lin, MD |
| Yuan-Hong Lin presents the findings on the impact of hyaluronic acid rectal spacers on rectal dosimetry and gastrointestinal toxicity outcomes in prostate cancer patients. This retrospective study analyzed data from 100 men treated with moderately hypofractionated external beam radiotherapy, focusing on the modified Spacer Symmetry Score and Fisher-Valuck spacer symmetry score to assess implant quality. |
|
|
|
|
|
| Rectal Wall Infiltration with Hyaluronic Acid Based Rectal Spacer Reversal Protocol
|
| Anne Hong, MD
|
| Anne Hong presents a retrospective analysis on the management of rectal wall infiltration following the use of stabilized hyaluronic acid rectal spacers in prostate cancer treatment. The study found that while rectal wall infiltration is uncommon, it can be safely managed through observation or reversal with hyaluronidase, and no significant complications were reported post-reversal.
|
|
|
|
|
|
| Hyaluronic Acid Rectal Spacer in Locally Recurrent Prostate Cancer with Prior Radiation Receiving SBRT: Feasibility, Safety, and Toxicity |
| LaToya McLean, MD |
| LaToya McLean presents a study on the use of hyaluronic acid rectal spacers in patients with locally recurrent prostate cancer who had previously undergone radiation and were receiving stereotactic body radiotherapy (SBRT). The study demonstrated that hyaluronic acid was successfully and safely injected in all patients, with no adverse events, providing adequate separation between the prostate and rectum in most cases. |
|
|
|
|
|
|
|
|
|
|
